Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday. Get Eikon Therapeutics alerts:Check Out Our Latest Report on EIKNEikon Therapeutics Trading Down 0.1%Shares of EIKN opened at $9.55 on Thursday. Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its earnings results on Monday, March 30th.